4D FDG PET in Esophageal Cancer

4D PET-CT Imaging in Esophageal Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02424864

Enrollment

Registered

2015-04-23

Start date

2014-08-31

Completion date

2017-05-19

Last updated

2017-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Keywords

4D PET-CT

Brief summary

FDG PET-CT image acquisition in the abdominal and thoracic region is influenced by organ motion. Respiratory movement blurs the metabolic signal of the esophageal tumor and lymph nodes. The investigators hypothesize that the metabolic signal obtained with motion compensation results in higher SUV-max values and clearer demarcation of the esophageal tumor and lymph nodes.

Detailed description

Patients will receive a normal 3D FDG PET-CT scan. By participating in this trial, one extra 4D CT scan will be made. For both the PET and the 4D CT acquisition, the patient gets an abdominal belt around the waist to register breathing motion. No extra FDG PET scan is required for this study. The 4D CT scan is the only intervention which increases the radiation dose exposure compared to the standard PET-CT scan. However, in comparison to the expected radiation dose delivered, if a patient will be treated with curative chemoradiotherapy, this increase in radiation dose is negligible and secondary risks due to this intervention are therefore not increased. For patients who are not eligible for curative treatment the extra dose is also not relevant, given the life expectancy of this group.

Interventions

OTHER4d PET-CT

Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with pathology proven esophageal cancer or tumor highly suspicious for esophageal cancer * \> 18 years * Written informed consent

Exclusion criteria

* \<18 years * Possibility of pregnancy

Design outcomes

Primary

Measure	Time frame
The estimation of tumor size of the primary esophageal tumor on 4Dvs 3D FDG PET	one year

Secondary

Measure	Time frame	Description
Measurement of SUV max, SUV mean, and SUV peak in 4D versus 3D images of esophageal cancer and lymph nodes and number of suspected involved lymph nodes	one year	measurement of the SUV is a composite measurement in each FDG PET scan

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026